Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
- Registration Number
- NCT00461591
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Brief Summary
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.
- Detailed Description
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study. Within 14 days of Screening, eligible patients underwent a TURBT during Visit 1 (Day 0) following which they were immediately randomized in a 1:1 ratio to receive either placebo or 4 mg apaziquone, instilled in a volume of 40 mL into the bladder within 6 hours from the end of the TURBT procedure. After a 60-minute retention period, study drug was drained from the bladder.
A postoperative follow-up examination and review of the local pathology report were performed at Visit 2, which occurred 21 days (±10 days) after the TURBT (Week 3).
* If the histology of the patient's tumor was confirmed as Ta, G1-G2 (ie, low grade according to World Health Organization \[WHO\]/International Society of Urologic Pathology \[ISUP\] classification), no further treatment was given and the patient was observed cystoscopically every 3 months through Year 2 for tumor recurrence (Visit 3 through Visit 10).
* If the histology of the patient's tumor was other than Ta, G1 or G2 (low grade \[WHO/ISUP classification\]), further treatment was given in accordance with current treatment guidelines, and the patient was followed up cystoscopically every 3 months through Year 2 for tumor recurrence (Visit 3 through Visit 10).
All patients were to be followed for 2 years.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 802
(All questions must be answered YES)
- Has the patient given written informed consent?
- Is the patient at least 18 years old?
- Does the patient have transitional cell carcinoma of the bladder with clinically apparent stage Ta, grade G1-G2?
- If the patient is a female of childbearing potential, is she using an acceptable/effective method of contraception?
- If the patient is a female of childbearing potential, has she had a negative serum pregnancy test within the past 14 days?
- Is the patient willing and able to abide by the protocol?
(All questions must be answered NO)
- Does the patient have more than 4 bladder tumors?
- Does any single bladder tumor exceed 3.5 cm in diameter?
- Does the patient have a single, primary (no previous diagnosis of TCC) bladder tumor <0.5 cm?
- Has the patient ever received Apaziquone?
- Does the patient have, or has the patient ever had, any bladder tumor known to be other than stage Ta or grade G1 or G2 (low grade [WHO/ISUP classification])?
- Does the patient have, or has the patient ever had any bladder tumor with histology other than transitional cell carcinoma?
- Does the patient have, or has the patient ever had, carcinoma in situ (CIS)?
- Does the patient have an active urinary tract infection?
- Does the patient have a bleeding disorder or a screening platelet count < 100 x 10^9/L?
- Does the patient have any unstable medical condition that would make it unsafe for him/her to undergo TURBT under general or spinal anesthesia?
- Does the patient have a screening hemoglobin < 10 mg/dL, a screening absolute neutrophil count < 1.5 x 10^9/L or a screening creatinine > 2 mg/dL?
- Does the patient have a known immunodeficiency disorder?
- Has the patient received any investigational treatment within the past 30 days?
- Is the patient breast feeding?
- Does the patient have a history of interstitial cystitis?
- Does the patient have a history of allergy to red color food dye?
- Has the patient had transitional cell carcinoma of the bladder within the past 4 months?
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT Placebo TURBT TURBT + a single intravesical dose of placebo instilled into the bladder post-TURBT Apaziquone TURBT TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT Apaziquone Apaziquone TURBT + a single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
- Primary Outcome Measures
Name Time Method Recurrence Rate at 2 Years 2 years The percentage of participants with histologically confirmed recurrence of the bladder tumor at any time after randomization and on or before year 2.
- Secondary Outcome Measures
Name Time Method Time to Progression 2 years The number of months from randomization to progression to either a higher stage or grade of the patient's bladder tumor.
Time to Recurrence 2 years The number of months from randomization to histologically confirmed recurrence of the patient's bladder tumor.
Progression Rate at 2 Years 2 years The percentage of participants that progress to either a higher stage or grade from the histologically confirmed stage and grade at time of randomization.
Number of Recurrences Per Patient 2 years The number of histologically confirmed recurrences during the course of the study.
Disease Free Interval 2 years The number of months from randomization to histologically confirmed progression of the patient's bladder tumor or death from any cause
Disease Free Survival 2 years The number of months from randomization to histologically confirmed recurrence of the patient's bladder tumor or death from any cause
Overall Survival 2 years The number of months from randomization to death from any cause.
Trial Locations
- Locations (72)
Alaska Clinical Research Center, LLC
🇺🇸Anchorage, Alaska, United States
BCG Oncology
🇺🇸Phoenix, Arizona, United States
Sun Health Research Institute
🇺🇸Sun City, Arizona, United States
Urology Associates Medical Group
🇺🇸Burbank, California, United States
Urology Associates of Central CA
🇺🇸Fresno, California, United States
South Orange County Medical Research Center
🇺🇸Laguna Woods, California, United States
Kaiser Permanente Los Angeles Medical Center
🇺🇸Los Angeles, California, United States
Cancer Research Dept/St. Joseph Hospital
🇺🇸Orange, California, United States
San Bernardino Urologic Association
🇺🇸San Bernardino, California, United States
VA Medical Center
🇺🇸San Francisco, California, United States
Scroll for more (62 remaining)Alaska Clinical Research Center, LLC🇺🇸Anchorage, Alaska, United States